This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial (PRROTECT)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Children's Hospital of Philadelphia
Stanford University
Ann & Robert H Lurie Children's Hospital of Chicago
Information provided by (Responsible Party):
Lynda Schneider, Boston Children's Hospital
ClinicalTrials.gov Identifier:
NCT01781637
First received: January 30, 2013
Last updated: May 2, 2017
Last verified: May 2017
  Purpose
The investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy. The investigators will determine if pretreatment with anti-IgE mAb (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer desensitization.

Condition Intervention Phase
Peanut Allergy Food Allergy Drug: Omalizumab Drug: placebo Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: Phase 2 Study of Omalizumab in Oral Peanut Desensitization

Resource links provided by NLM:


Further study details as provided by Lynda Schneider, Boston Children's Hospital:

Primary Outcome Measures:
  • Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo [ Time Frame: 6 weeks after last dose of omalizumab/placebo ]

Secondary Outcome Measures:
  • Pass 4000 mg OFC 12 Weeks After Last Dose of Omalizumab/Placebo [ Time Frame: 12 weeks after last dose of omalizumab/placebo ]

Enrollment: 36
Study Start Date: January 2013
Estimated Study Completion Date: October 2017
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: omalizumab group
Patients will receive omalizumab.
Drug: Omalizumab
subcutaneous injection
Other Name: Xolair
Placebo Comparator: placebo
Patients will receive placebo.
Drug: placebo
subcutaneous injection

Detailed Description:

36 subjects will receive Xolair, and 8 subjects will receive placebo. The study will occur at 4 sites: Boston Children's Hospital, Children's Hospital of Philadelphia, Stanford University and Lurie Children's Hospital.

Patients will be pre-treated with Xolair or placebo before rapid oral peanut desensitization. Patients will continue to receive Xolair during the 8 subsequent weeks of desensitization, receiving their final dose of Xolair one week after reaching the highest tolerated dose of peanut.

  Eligibility

Ages Eligible for Study:   7 Years to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Moderate to severe peanut allergy-sensitive subjects between the ages of 7 to 25 years old.
  • Sensitivity to peanut allergen will be documented by a positive skin prick test result (6 mm diameter wheal or greater)
  • ImmunoCAP IgE level to peanut > 10 kU/L.
  • Sensitivity to peanut allergen based on a double-blind placebo-controlled oral food challenge (DBPCFC) at maximum of cumulative 175 mg of peanut protein dose.

Exclusion Criteria:

  • Subjects with a total IgE at screening of < 50 kU/L > 2,000 kU/L.
  • Positive reaction to the placebo on DBPCFC.
  • Previous reaction to omalizumab.
  • Subjects having a history of severe anaphylaxis to peanut requiring intubation or admission to an ICU, frequent allergic or non-allergic urticaria, or history consistent with poorly controlled persistent asthma, or gastrointestinal or gastroesophageal disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01781637

Locations
United States, California
Stanford University
Stanford, California, United States, 94305
United States, Illinois
Lurie Children's Hospital
Chicago, Illinois, United States, 60611
United States, Massachusetts
Division of Immunology, Children's Hospital Boston
Boston, Massachusetts, United States, 02115
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Boston Children’s Hospital
Children's Hospital of Philadelphia
Stanford University
Ann & Robert H Lurie Children's Hospital of Chicago
Investigators
Principal Investigator: Lynda C Schneider, MD Boston Children’s Hospital
Study Chair: Andrew MacGinnitie, MD, PhD Children' Hospital Boston
Study Chair: Kari Nadeau, MD, PhD Stanford University
Study Chair: Jonathan Spergel, MD, PhD Children's Hospital of Philadelphia
Study Chair: Jacqueline Pongracic, MD Lurie Children's Hospital
  More Information

Responsible Party: Lynda Schneider, Associate Professor, Harvard Medical School, Boston Children's Hospital
ClinicalTrials.gov Identifier: NCT01781637     History of Changes
Other Study ID Numbers: Peanut 002
Study First Received: January 30, 2013
Results First Received: March 23, 2017
Last Updated: May 2, 2017

Keywords provided by Lynda Schneider, Boston Children's Hospital:
Xolair
omalizumab
peanut
oral desensitization

Additional relevant MeSH terms:
Hypersensitivity
Food Hypersensitivity
Peanut Hypersensitivity
Immune System Diseases
Hypersensitivity, Immediate
Omalizumab
Anti-Allergic Agents
Anti-Asthmatic Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on June 23, 2017